# Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Study · id `cardio:ct-nct03195673` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03195673](<https://clinicaltrials.gov/study/NCT03195673>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03195673

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT03195673. Randomized; double masking; primary purpose prevention. Start 2018-03-02 (actual); primary completion 2019-11-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT03195673, source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)
- Started: 2018-03-02 (actual) (ClinicalTrials.gov record NCT03195673, source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)
- Primary completion: 2019-11-15 (anticipated) (ClinicalTrials.gov record NCT03195673, source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)
- Completion: 2019-12-15 (anticipated) (ClinicalTrials.gov record NCT03195673, source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03195673, source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03195673-2018-12-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
- Acronym: TZ-CAS
- Condition: Carotid Artery Stenosis
- Intervention (Drug): Terazosin
- Intervention (Procedure): Carotid artery stenting
- Lead sponsor: Capital Medical University
- Lead sponsor class: OTHER
- Collaborator: The Luhe Teaching Hospital of the Capital Medical University
- Collaborator class: OTHER
- Collaborator: Beijing Anzhen Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry lists this organization as the lead sponsor: Capital Medical University (`cardio:org-capital-medical-university`)
- Registry lists this organization as a collaborator: The Luhe Teaching Hospital of the Capital Medical University (`cardio:org-the-luhe-teaching-hospital-of-the-capital-medical-university`)
- Registry lists this organization as a collaborator: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 6c480193a0527483601b7aa8be408dacc4a5353f453aa15c7100b8864ccf7c21
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
